IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Melanoma | Drug: LGX818 | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma |
- Tumor Response (Overall Response Rate) Per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Part I & Part II) [ Time Frame: Baseline through study completion (approximately 2 years) ]
Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define the status of tumors in cancer patients during a specific treatment.
The Overall Response Rate was calculated according to the RECIST criteria, as per investigator assessment.
Per RECIST guidelines:
- Complete Response (CR) is the Disappearance of all target lesions.
- Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions.
- Progressive Disease (PD) is the at least a 20% increase in the sum of diameters of target lesions.
- Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
- Incidence of Dose Limiting Toxicities (DLTs) (Part II) [ Time Frame: Baseline through study completion (approximately 2 years) ]Incidence of DLTs in Part II of the study was not evaluated due to an inadequate number of patients enrolled in Part II prior to the permanent recruitment halt of this study.
- Plasma Concentration and Derived Pharmacokinetic Parameters [ Time Frame: Baseline through study completion (approximately 2 years) ]Assessment of pharmacokinetic (PK) parameters and plasma concentration was not done due to an inadequate number of patients enrolled in Part II prior to the permanent recruitment halt of this study.
- Tumor Response (Overall Response Rate) Via Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Part I) [ Time Frame: Baseline through completion of Part I of the study (approximately 2 years) ]
Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define the status of tumors in cancer patients during a specific treatment.
The Overall Response Rate was calculated according to the RECIST criteria, as per investigator assessment.
Per RECIST guidelines:
- Complete Response (CR) is the Disappearance of all target lesions.
- Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions.
- Progressive Disease (PD) is the at least a 20% increase in the sum of diameters of target lesions.
- Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
- Tumor Response (Overall Response Rate) Via Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 (Part II) [ Time Frame: Entry to Part II of the study through study completion (approximately 22 days) ]
Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define the status of tumors in cancer patients during a specific treatment.
The Overall Response Rate was calculated according to the RECIST criteria, as per investigator assessment.
Per RECIST guidelines:
- Complete Response (CR) is the Disappearance of all target lesions.
- Partial Response (PR) is at least a 30% decrease in the sum of diameters of target lesions.
- Progressive Disease (PD) is the at least a 20% increase in the sum of diameters of target lesions.
- Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
One patient with documented PD at study Day 146 entered into Part II of the study and received combination treatment of LGX818 450 mg plus MEK162 45 mg for two weeks. The patient experienced disease progression on Day 22 of Part II and discontinued the study.
- Molecular Status of Markers Relevant to the RAP/MEK/ERK and PI3K/AKT Pathways [ Time Frame: Baseline and at progression with LGX818 single agent treatment ]Molecular status was not evaluated due to an inadequate number of patients enrolled in Part II prior to the permanent recruitment halt of this study.
| Enrollment: | 15 |
| Study Start Date: | November 2013 |
| Study Completion Date: | March 2015 |
| Primary Completion Date: | March 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: LGX818 single agent
Patients had to have written documentation of a BRAFV600 mutation, which was to have been obtained locally on a fresh tumor biopsy (preferred) or on the most recent archival tumor sample available.
|
Drug: LGX818
BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
Other Name: encorafenib
|
Detailed Description:
This is a phase II two part multi-center, open-label study. Part I: LGX818 single agent treatment until progression Part II: Combination treatments of LGX818 + MEK162, or BKM120, or BGJ398, or INC280, or LEE01 to assess the clinical efficacy, to further evaluate the safety of the drug combinations in patients with locally advanced or metastatic BRAF mutant melanoma after relapse on LGX818, and to determine the maximum tolerated dose of the combinations (when not established previously). These drug combinations are selected and assigned to patients based on documentation of molecular resistance mechanism.
Patients with BRAF mutant melanoma treated by LGX818 single agent in other studies can be enrolled directly in Part II of CLGX818X2102 after relapse.
Dose-escalations in the combination arms for which no MTD has been established will be based on the recommendations of a Bayesian logistic regression model guided by an escalation with overdose control criterion.
After careful evaluation of slow enrollment and the BRAF-mutant melanoma treatment landscape, recruitment was permanently halted on 26-Jul-2014.
This recruitment halt was not a consequence of any safety concern and patients who were ongoing in the study continued to be treated as per protocol.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- locally advanced or metastatic melanoma
- confirmed BRAF V600 mutation
- patients naïve to a selective BRAF inhibitor
- fresh tumor biopsy at baseline, and patient agrees for a mandatory biopsy at the time of relapse
- life expectancy ≥ 3 months
- World Health Organization (WHO) Performance Status ≤ 2.
Exclusion Criteria:
- Previous treatment with RAF-inhibitor
- Symptomatic or untreated leptomeningeal disease
- Symptomatic brain metastases.
- Known acute or chronic pancreatitis
- Clinically significant cardiac disease
- AST/SGOT and ALT/SGPT > 2.5 x ULN, or > 5 x ULN if liver metastases are present
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral interventional drug
- Previous or concurrent malignancy.
- Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
Specific exclusion criteria for each treatment arm:
LGX818/MEK162:
History or current evidence of retinal disease History of Gilbert's syndrome.
LGX818/BKM120:
Patients with diabetes mellitus requiring insulin treatment Patient has mood disorders
LGX818/BGJ398:
History and/or current evidence of ectopic mineralization/ calcification Current evidence of corneal disorder/ keratopathy Patients with current evidence of endocrine alteration of calcium/phosphate homeostasis.
History of congenital long QT- syndrome and/or hypokalaemia CTCAE Grade ≥ 3 and/or magnesium levels below the clinically relevant lower limits before study entry.
Ionized (i) calcium (Ca) > ULN Serum inorganic phosphorus (Pi) > ULN
LGX818/LEE011 History of congenital long QT- syndrome and/or hypokalaemia CTCAE Grade ≥ 3 and/or magnesium levels below the clinically relevant lower limits before study entry.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01820364
| United States, Tennessee | |
| Sarah Cannon Research Institute Onc Dept | |
| Nashville, Tennessee, United States, 37203 | |
| Australia, Victoria | |
| Novartis Investigative Site | |
| East Melbourne, Victoria, Australia, 3002 | |
| Canada, Alberta | |
| Novartis Investigative Site | |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Germany | |
| Novartis Investigative Site | |
| Heidelberg, Germany, 69120 | |
| Spain | |
| Novartis Investigative Site | |
| Barcelona, Catalunya, Spain, 08035 | |
| Switzerland | |
| Novartis Investigative Site | |
| Zuerich, Switzerland, 8091 | |
| Study Director: | Array BioPharma | 303-381-6604 |
More Information
| Responsible Party: | Array BioPharma |
| ClinicalTrials.gov Identifier: | NCT01820364 History of Changes |
| Other Study ID Numbers: |
CLGX818X2102 2012-004798-17 ( EudraCT Number ) |
| Study First Received: | March 25, 2013 |
| Results First Received: | April 13, 2016 |
| Last Updated: | November 10, 2016 |
Keywords provided by Array BioPharma:
|
open-label study BRAF inhibitor LGX818 MEK1620 MAPK1/2 inhibitor Pi3K inhibitor |
FGFR c-Met CDK4/6 metastatic melanoma BRAF V600 |
Additional relevant MeSH terms:
|
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas |
ClinicalTrials.gov processed this record on June 26, 2017